MedTrace Logo

Regular Use Effect of Inhaled Ipratropium Bromide on Airway Responsiveness to Methacholine in Well-controlled Asthma

NCT04167280 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2020-03-26

No results posted yet for this study

Summary

Study is looking at the development of tolerance to methacholine following regular use of ipratropium bromide in mild asthmatics.

Conditions

Interventions

DRUG

Ipratropium Metered Dose Inhaler

MDI to deliver 20mcg per puff ipratropium bromide

DRUG

placebo metered dose inhaler

matched MDI to deliver inactive drug

Sponsors & Collaborators

  • University of Saskatchewan

    lead OTHER

Principal Investigators

  • Don Cockcroft, MD · University of Saskatchewan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-05
Primary Completion
2020-03-13
Completion
2020-03-13

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04167280 on ClinicalTrials.gov